Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17877864 | 0.96 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 | |
| SCHEMBL17875821 | 0.96 | FLT3 (0.41) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 | |
| SCHEMBL17877733 | 0.90 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 | |
| SCHEMBL17875918 | 0.90 | FLT3 (0.37) | CYP11B2CYP11B1FLT3CYP19A1 | |
| SCHEMBL17877777 | 0.90 | PRKDC (0.34) | — | |
| SCHEMBL17875884 | 0.90 | CYP11B1 (0.40) | CYP11B2CYP11B1CYP17A1CYP1A2CYP19A1 | |
| SCHEMBL17877880 | 0.89 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 | |
| SCHEMBL17877842 | 0.89 | FLT3 (0.41) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 | |
| SCHEMBL17877726 | 0.87 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 | |
| SCHEMBL17875731 | 0.87 | FLT3 (0.41) | CYP11B2CYP11B1CYP17A1FLT3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNE2 | CYP11B2 1374/4885CYP11B1 938/4885CYP17A1 909/4885 |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | CYP11B2 1374/4885CYP11B1 938/4885CYP17A1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.